Compare PCRX & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ORC |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2011 | 2013 |
| Metric | PCRX | ORC |
|---|---|---|
| Price | $26.50 | $7.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $32.86 | N/A |
| AVG Volume (30 Days) | 723.2K | ★ 5.6M |
| Earning Date | 11-06-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 20.20% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.47 | ★ 0.57 |
| Revenue | ★ $716,791,000.00 | $80,187,000.00 |
| Revenue This Year | $6.24 | $82.99 |
| Revenue Next Year | $9.53 | $61.79 |
| P/E Ratio | $55.78 | ★ $12.43 |
| Revenue Growth | 3.14 | ★ 5.93 |
| 52 Week Low | $18.17 | $5.69 |
| 52 Week High | $27.64 | $9.01 |
| Indicator | PCRX | ORC |
|---|---|---|
| Relative Strength Index (RSI) | 73.86 | 45.62 |
| Support Level | $25.17 | $7.09 |
| Resistance Level | $24.81 | $7.41 |
| Average True Range (ATR) | 0.94 | 0.10 |
| MACD | 0.28 | -0.01 |
| Stochastic Oscillator | 89.16 | 26.98 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.